The RGLS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the RGLS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The RGLS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
![]() |
View RGLS Detailed Price Forecast - CNN Money | ![]() |
View RGLS Detailed Summary - Google Finance |
![]() |
View RGLS Detailed Summary - Yahoo! Finance | ![]() |
View RGLS Stock Research & Analysis - Zacks.com |
![]() |
View RGLS Trends & Analysis - Trade-Ideas | ![]() |
View RGLS Major Holders - Barrons |
![]() |
View RGLS Call Transcripts - NASDAQ | ![]() |
View RGLS Breaking News & Analysis - Seeking Alpha |
![]() |
View RGLS Annual Report - CompanySpotlight.com | ![]() |
View RGLS OTC Short Report - OTCShortReport.com |
![]() |
View RGLS Fundamentals - TradeKing | ![]() |
View RGLS SEC Filings - Bar Chart |
![]() |
View Historical Prices for RGLS - The WSJ | ![]() |
View Performance/Total Return for RGLS - Morningstar |
![]() |
View the Analyst Estimates for RGLS - MarketWatch | ![]() |
View the Earnings History for RGLS - CNBC |
![]() |
View the RGLS Earnings - StockMarketWatch | ![]() |
View RGLS Buy or Sell Recommendations - MacroAxis |
![]() |
View the RGLS Bullish Patterns - American Bulls | ![]() |
View RGLS Short Pain Metrics - ShortPainBot.com |
![]() |
View RGLS Stock Mentions - StockTwits | ![]() |
View RGLS Stock Mentions - PennyStockTweets |
![]() |
View RGLS Stock Mentions - Twitter | ![]() |
View RGLS Investment Forum News - Investor Hub |
![]() |
View RGLS Stock Mentions - Yahoo! Message Board | ![]() |
View RGLS Stock Mentions - Seeking Alpha |
![]() |
View Insider Transactions for RGLS - SECform4.com | ![]() |
View Insider Transactions for RGLS - Insider Cow |
![]() |
View RGLS Major Holdings Summary - CNBC | ![]() |
View Insider Disclosure for RGLS - OTC Markets |
![]() |
View Insider Transactions for RGLS - Yahoo! Finance | ![]() |
View Institutional Holdings for RGLS - NASDAQ |
![]() |
View RGLS Stock Insight & Charts - FinViz.com | ![]() |
View RGLS Investment Charts - StockCharts.com |
![]() |
View RGLS Stock Overview & Charts - BarChart | ![]() |
View RGLS User Generated Charts - Trading View |
Regulus Announces Clinical Candidate Nomination for the Treatment of Glioblastoma Multiforme
Posted on Monday January 07, 2019
Standard of care temozolomide as a single agent increased median survival by 27% vs. control, therefore the combination of RGLS5579 plus temozolomide demonstrated synergistic efficacy in this model. RGLS5579 has completed the clinical candidate screening process demonstrating appropriate preliminary safety and drug-like properties.
Regulus Announces Preliminary Results of Planned Interim Data Analysis of RGLS4326 in New Mouse Chronic Toxicity Study
Posted on Friday January 04, 2019
LA JOLLA, Calif., Jan. 4, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the preliminary results of a planned interim data analysis from the new mouse chronic toxicity study of RGLS4326 in development for the treatment of Autosomal Dominant Polycystic Kidney Disease, or ADPKD. As previously reported by the Company in July 2018, and in consultation with FDA, the Company voluntarily paused its ongoing Phase 1 Multiple Ascending Dose ("MAD") study of RGLS4326 in healthy volunteers due to unexpected observations in the 27-week mouse chronic toxicity study. The Company terminated that mouse study prematurely at week 14. The study was run in parallel to the Phase 1 program to enable initiation of the Phase 2 program in ADPKD patients upon completion of the Phase 1 MAD study.
Need To Know: Regulus Therapeutics Inc. (NASDAQ:RGLS) Insiders Have Been Buying Shares
Posted on Thursday December 20, 2018
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to mention Read More...
Research Report Identifies Advanced Energy Industries, Altair Engineering, Rambus, Regulus Therapeutics, NN, and Halcon Resources with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
Posted on Wednesday November 28, 2018
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.